Innovations in Cancer Treatment in Germany: What Are FAPI and EphA2 PET, and How Can They Help When Other Methods Fail?
When facing a cancer diagnosis, timing and accuracy are critical. Standard imaging techniques, such as CT, MRI, or conventional FDG PET/CT, are valuable diagnostic tools. However, they can sometimes miss small metastatic foci or fail to explain why a previously effective treatment has stopped working.
Leading university hospitals in Germany actively utilize next-generation molecular imaging technologies: FAPI PET and EphA2 PET. These advanced modalities combine ultra-precise diagnostics with targeted therapy (Theranostics). Put simply, specialists first "illuminate" the tumor on a specialized scanner and then deliver targeted radionuclide therapy ("precision medicine") directly to those specific tumor cells from within.
1. FAPI PET (Fibroblast Activation Protein Inhibitor): Visualizing the Tumor Microenvironment
How Does FAPI PET Work?
Conventional FDG PET/CT detects cancer by measuring how rapidly cells metabolize glucose (sugar). However, certain tumors do not consume high amounts of sugar, or they reside in organs with naturally high background glucose uptake (such as the liver, brain, or gastrointestinal tract), creating diagnostic "blind spots."
FAPI PET operates on a different mechanism. Tumors consist not only of malignant cells but also of a supportive stroma created by Cancer-Associated Fibroblasts (CAFs). FAPI specifically targets the Fibroblast Activation Protein (FAP) expressed on these cells, binding to the tumor microenvironment with high affinity and causing it to stand out with exceptional clarity on PET scans.
Clinical Indications for FAPI PET
- Gastrointestinal & Hepatobiliary Cancers: Pancreatic cancer (PDAC), gastric cancer, colorectal cancer, and cholangiocarcinoma.
- Gynecological Malignancies: Ovarian cancer, cervical cancer, and endometrial cancer.
- Complex & Rare Malignancies: Breast cancer, lung cancer, and sarcomas.
- Detection of Occult Metastases: FAPI PET exhibits superior sensitivity in identifying peritoneal carcinomatosis (pelvic and abdominal lining metastases) and liver micro-metastases that remain undetected on conventional CT or MRI scans.
- Cancer of Unknown Primary (CUP Syndrome): Locating primary tumor sites when metastases have already been identified.
Therapeutic Applications (FAPI Radioligand Therapy)
If a FAPI PET scan confirms high FAP expression, German oncologists can offer targeted FAPI radioligand therapy. By replacing the diagnostic isotope with a therapeutic radionuclide—such as Lutetium-177 or Actinium-225—the radiopharmaceutical delivers localized radiation directly to the tumor stroma, sparing surrounding healthy tissues.
Availability in Germany
In Germany, FAPI therapy is available at major university centers under Compassionate Use / expanded access programs for patients who have exhausted standard chemotherapy options.
2. EphA2 PET (Ephrin Type-A Receptor 2): Targeting Aggressive and Resistant Tumors
How Does EphA2 PET Work?
EphA2 is a transmembrane receptor tyrosine kinase that is overexpressed on aggressive, rapidly growing cancer cells and tumor-associated blood vessels. In healthy adult tissues, EphA2 expression is minimal. EphA2 PET imaging allows clinicians to assess tumor aggressiveness, invasive potential, and resistance to prior chemotherapy regimens.
Clinical Indications for EphA2 PET
- Aggressive Pancreatic Ductal Adenocarcinoma (PDAC).
- Glioblastoma (high-grade brain tumors).
- Triple-Negative Breast Cancer (TNBC).
- Chemotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC).
Therapeutic Applications
EphA2 serves as a molecular target for cutting-edge targeted therapeutics, including alpha- and beta-emitting radionuclides, antibody-drug conjugates (ADCs), and novel EphA2-targeted CAR-T cell therapies.
Availability in Germany
While FAPI PET is already integrated into clinical practice for individual patient care in Germany, EphA2 PET and its corresponding therapies are primarily accessible through early-phase clinical trials (Phase I/II) at specialized German university medical centers.
Comparison: FAPI vs. EphA2 PET
The primary difference between these two innovative approaches lies in their biological targets:
- FAPI PET targets the tumor "framework" and surrounding microenvironment (stroma). This provides extremely high target-to-background contrast, making it ideal for detecting subtle peritoneal, hepatic, and osseous metastases. FAPI procedures are available in German medical centers based on individual clinical indications.
- EphA2 PET directly targets the malignant cells and tumor vasculature itself. This makes it an invaluable diagnostic tool for identifying highly aggressive, invasive, and chemo-resistant tumor clones. EphA2 imaging and therapy are available mainly through specialized research programs at university centers in Germany.
Seeking Medical Care or Advanced Diagnostics in Germany?
Send us your complete medical records (medical summaries, clinical history, and recent CT/MRI/PET scans). Our team will rapidly evaluate your case, consult with leading professors at top German university centers, and help arrange expert FAPI or EphA2 PET diagnostics and targeted therapy.